Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment.

doi:10.1002/ajh.27417

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment.

American journal of hematology - 1 Oct 2024

Garciaz Sylvain, Dumas Pierre-Yves, Bertoli Sarah, Sallman David A, Decroocq Justine, Belhabri Amine, Orvain Corentin, Aspas Requena Gaspar, Simand Celestine, Laribi Kamel, Carré Martin, Santagostino Alberto, Himberlin Chantal, Peterlin Pierre, Bonnet Sarah, Chan Onyee, Lancet Jeffrey, Komrokji Rami, Vergez François, Chapuis Nicolas, Raskovalova Tatiana, Plesa Adriana, Lhoumeau Anne-Catherine, Mineur Ariane, Hospital Marie Anne, Pigneux Arnaud, Vey Norbert, Récher Christian

Abstract excerpt

Venetoclax-azacitidine is the standard of treatment for unfit acute myeloid leukemia patients. In the VIALE-A study, treatment was given until progression but there are no data on its optimal duration for responding patients who do not tolerate indefinite therapy. We retrospectively analyzed the outcome of patients who discontinued venetoclax or venetoclax-azacitidine due to poor tolerance. Sixty-two newly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Azacitidine

Share to Bridged Bicyclo Compounds, Heterocyclic

Share to Disease-Free Survival

Share to Isocitrate Dehydrogenase

Share to Leukemia, Myeloid, Acute

Share to Sulfonamides

Share to Treatment Outcome

Source

Open in PubMed

Identifiers

PMID: 38899566
DOI: 10.1002/ajh.27417

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment.PMID 38899566Read ↗

Long-Term Follow-up of the Phase 3 Viale-a Clinical Trial of Venetoclax Plus Azacitidine for Patients with Untreated Acute Myeloid Leukemia Ineligible for Intensive ChemotherapySemantic proximity Read ↗

Reduced Duration and Dosage of Venetoclax Is Efficient in Newly Diagnosed Patients with Acute Myeloid LeukemiaSemantic proximity Read ↗

Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine–venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia NetSemantic proximity Read ↗

Real-life multicenter experience of long-term treatment with venetoclax plus azacitidine for acute myeloid leukemia in China.Semantic proximity Read ↗

Efficacy and safety of venetoclax and azacitidine for acute myeloid leukemia in China: a real-world single-center studySemantic proximity Read ↗

Efficacy of venetoclax and azacitidine based therapy in favorable-risk unfit acute myeloid leukemia: a real-world studySemantic proximity Read ↗

Cytopenia Management in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Azacitidine in the VIALE-A StudySemantic proximity Read ↗

Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.Semantic proximity Read ↗

Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia.Semantic proximity Read ↗

Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study.Semantic proximity Read ↗

Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy.Semantic proximity Read ↗

Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.